HAMP and acquired polycythemia vera: Furthermore, a Phase II clinical trial using PTG-300, another hepcidin-mimetic agent, demonstrates HCT control without therapeutic phlebotomy and reverses systemic iron deficiency in PV patients with high therapeutic phlebotomy requirements [13].